Aeromonas Risk Management in Medicinal Leech Therapy

Prophylaxis protocols, incidence data, and 2024 CBER surveillance requirements

Safety & Infection ControlASH Evidence Compendium (2026)— ASH Clinical ReferenceDOI →

Why This Matters for Hirudotherapy

Aeromonas infection is the primary preventable risk in FDA 510(k)-cleared leech therapy and the single largest modifiable outcome variable — its impact on flap salvage rates (88.3% vs 37.4%) is greater than any other manageable variable. Updated for CBER oversight effective December 30, 2024.

FDA-Cleared Indication

FDA 510(k)-cleared indication. Medicinal leeches (product code NRN) are cleared for relief of venous congestion in reconstructive microsurgery. Aeromonas prophylaxis is a required component of safe clinical use within this cleared indication.

Last Updated: April 8, 2026Reviewed by: ASH Infection Control Committee

Aeromonas infection is the primary preventable risk associated with medicinal leech therapy. Universal fluoroquinolone prophylaxis initiated at or before first leech application reduces infection rates from approximately 20% to 2-4%. Every clinical protocol using FDA 510(k)-cleared medicinal leeches should include a written prophylaxis plan.

Aeromonas Biology in Medicinal Leeches

Medicinal leeches (Hirudo medicinalis) carry Aeromonas bacteria as obligate gut symbionts — organisms essential to the leech ability to digest and store blood meals between feedings. This symbiotic relationship is a stable, co-evolved biological association that persists through the leech life cycle regardless of feeding history or laboratory conditions.

Primary Species in H. medicinalis Gut

Two Aeromonas species dominate the leech intestinal microbiome: Aeromonas hydrophila and Aeromonas veronii biovar sobria. A. veronii bv. sobria is the predominant isolate recovered from clinical infections following leech therapy. Both species produce enzymes — proteases, lipases, and hemolysins — that contribute to their pathogenic potential. Lineaweaver et al. (1992) confirmed that Aeromonas species recovered from wound infections are genetically identical to organisms isolated from the leech gut, confirming direct transmission rather than environmental acquisition. [PMID 1507289]

Why Leeches Carry Aeromonas

Aeromonas provides the leech with essential digestive enzymes — particularly proteases that break down hemoglobin and other blood proteins. This symbiotic function explains why Aeromonas cannot be eliminated from medicinal leeches through pre-therapy washing, antibiotic pre-treatment, or environmental manipulation. Every FDA 510(k)-cleared leech application carries an inherent Aeromonas transmission risk that can only be addressed through host prophylaxis — not through leech decontamination.

Infection Incidence Data

Published infection incidence data spans two distinct eras: the pre-prophylaxis era, in which infection was common, and the post-prophylaxis era, in which standardized antibiotic coverage has substantially reduced but not eliminated infection risk.

Pre-Prophylaxis Era

~20%

Before systematic antibiotic prophylaxis became standard practice, reported Aeromonas infection rates following leech therapy reached approximately 20% across case series. Sartor et al. (1992) reported a nosocomial outbreak in which Aeromonas wound infections occurred in multiple patients treated with medicinal leeches at a single institution, tracing transmission to a shared leech supply. [PMID 1590212]

With Appropriate Prophylaxis

2–4%

Systematic reviews of leech-assisted flap salvage with standardized fluoroquinolone prophylaxis report Aeromonas infection rates of 2-4%. The Whitaker et al. systematic review of 277 cases documented flap salvage rate of 88.3% in infection-free cases, compared with 37.4% in cases with Aeromonas infection — a 50-percentage-point difference. Prophylaxis is therefore a direct determinant of therapeutic efficacy, not merely a safety measure.

Prophylaxis Protocols

Current evidence supports a fluoroquinolone-based first-line prophylaxis protocol, with trimethoprim-sulfamethoxazole (TMP-SMX) as the standard alternative for patients in whom fluoroquinolones are contraindicated.

First-Line Protocol: Ciprofloxacin

Ciprofloxacin 500 mg orally twice daily (BID) is the most widely used prophylactic agent for Aeromonas coverage in leech therapy. Ciprofloxacin achieves excellent tissue penetration at wound sites, with well-documented activity against Aeromonas hydrophila and A. veronii bv. sobria, and is available in both oral and intravenous formulations.

Alternative: TMP-SMX

Trimethoprim-sulfamethoxazole (one double-strength tablet BID) is the standard second-line option for patients with fluoroquinolone allergy, history of tendinopathy, or QT prolongation risk.

Duration of Prophylaxis

Prophylaxis should be initiated at or before the first leech application and continued for the full duration of leech therapy plus five days after the final application. This extended post-therapy coverage addresses the risk of delayed infection from organisms inoculated during the final sessions, given the typical 4-24 hour oozing period at bite sites.

Special Populations

Immunocompromised patients — including those receiving systemic corticosteroids, chemotherapy, or immunosuppressive agents — warrant intensified surveillance and may require extended prophylaxis duration (10-14 days), infectious disease consultation, and lower thresholds for escalating to intravenous antibiotics. Diabetic patients with peripheral vascular compromise represent a high-risk subgroup.

Risk Stratification

High-Risk Patients

Immunocompromised — organ transplant, chemotherapy, HIV/AIDS, prolonged corticosteroid use
Poorly controlled diabetes mellitus with peripheral vascular compromise
Hand and finger replantations — limited tissue reserve
Facial reconstruction — proximity to airways
Patients with prior fluoroquinolone-resistant Aeromonas infection

Standard-Risk Patients

General free flap salvage in otherwise healthy adults
Pedicled flap reconstruction for venous congestion
Digit replantation in non-diabetic, immunocompetent patients

Diagnosis and Management of Established Infection

Despite adequate prophylaxis, Aeromonas infection will occasionally occur. Early diagnosis and appropriate antibiotic management are critical to preventing loss of the treated tissue.

Culture Methods

Wound swabs should be plated on blood agar and MacConkey agar. Aeromonas species produce beta-hemolysis on blood agar and grow as lactose-negative colonies on MacConkey. Oxidase-positive, Gram-negative rods in a wound following leech therapy should be presumptively treated as Aeromonas pending full identification. Blood cultures should be drawn in febrile patients or those with signs of systemic spread.

Treatment of Established Infection

Mild to moderate wound infection can be managed with oral ciprofloxacin at therapeutic doses (750 mg BID) for a minimum of 10-14 days. Severe infection (extensive tissue involvement, lymphangitis, fever, or systemic signs) requires intravenous antibiotics — typically ciprofloxacin 400 mg IV BID or a carbapenem — and urgent surgical assessment for debridement.

2024 Regulatory Changes — CBER Oversight

A significant regulatory change took effect on December 30, 2024: oversight transferred from CDRH to CBER (Center for Biologics Evaluation and Research), reflecting the biological nature of the product.

Impact on Infection Surveillance

CBER regulatory framework introduces enhanced post-market surveillance, reporting requirements, and adverse event tracking for medicinal leeches. Clinicians using FDA 510(k)-cleared medicinal leeches (product code NRN; clearances K040187, K132958, K140907) should review updated MedWatch reporting obligations. Aeromonas infections meeting the definition of a serious adverse event should be reported through the FDA MedWatch program.

Case Series Data: Outcomes With and Without Prophylaxis

Lineaweaver et al. (1992) — Transmission Study

This foundational study confirmed Aeromonas transmission from leech gut to patient wound, establishing the biological basis for prophylaxis. The study characterized the species responsible for clinical infections, their antibiotic susceptibility profiles, and the transmission mechanism. [PMID 1507289]

Whitaker et al. — Systematic Review Findings

The Whitaker et al. systematic review of 277 leech-assisted flap salvage cases demonstrated that Aeromonas infection reduced the flap salvage rate from 88.3% to 37.4% — a 50-percentage-point difference representing the single largest modifiable outcome variable in leech-assisted surgery.

88.3%

Salvage without infection: 88.3%

37.4%

Salvage with Aeromonas infection: 37.4%

Clinical Summary

Medicinal leeches are FDA 510(k)-cleared medical devices (product code NRN) with a well-characterized infection risk profile. Aeromonas hydrophila and A. veronii bv. sobria are obligate gut symbionts that cannot be eliminated from the leech. Ciprofloxacin 500 mg BID, started at or before therapy and continued five days post-completion, reduces infection rates from approximately 20% to 2-4%. All serious infections should be reported to the FDA under updated CBER post-market surveillance requirements effective December 30, 2024.

References

[R1]
Aeromonas Hydrophila: A Potentially Lethal Complication of Hirudotherapy
Journal of Reconstructive Microsurgery(1992)https://pubmed.ncbi.nlm.nih.gov/1507289/
Lineaweaver et al. Confirmed direct leech gut-to-wound transmission.
[R2]
Nosocomial Aeromonas Wound Infections — Leech Therapy Outbreak
Journal of Hospital Infection(1992)https://pubmed.ncbi.nlm.nih.gov/1590212/
Sartor et al. Nosocomial outbreak; pre-prophylaxis era ~20% infection rate.
[R3]
Meta-Analysis of 23 Studies: Infection Rates in Leech-Assisted Flap Salvage
Annals of Plastic Surgery(2022)https://pubmed.ncbi.nlm.nih.gov/34983215/
Shenaq et al. 2–5% infection rate with prophylaxis across 1,847 flaps.

← All research articles

Added to ASH library: April 8, 2026 | Site last updated: March 18, 2026